4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylcycloheptanone | 874379-66-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylcycloheptanone
• 英文别名: 4-[[3,5-bis(trifluoromethyl)phenyl]methoxymethyl]-4-phenylcycloheptan-1-one
• CAS: 874379-66-5
• 化学式: C₂₃H₂₂F₆O₂
• 分子量: 444.417
• InChiKey: NXQXLBUCNUWDBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylcycloheptanone 在 sodium azide 、 硼烷四氢呋喃络合物 、 三氟乙酸 作用下， 以 四氢呋喃 、 水 、 苯 为溶剂， 反应 6.0h， 生成 5-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-5-phenylazocane
  参考文献：
  名称：

  Discovery of disubstituted piperidines and homopiperidines as potent dual NK 1 receptor antagonists–serotonin reuptake transporter inhibitors for the treatment of depression

  摘要：

  This report describes the synthesis, structure-activity relationships and activity of piperidine, homopiperidine, and azocane derivatives combining NK1 receptor (NK1R) antagonism and serotonin reuptake transporter (SERT) inhibition. Our studies culminated in the discovery of piperidine 2 and homopiperidine 8 as potent dual NK1R antagonists-SERT inhibitors. Compound 2 demonstrated significant activity in the gerbil forced swimming test, suggesting that dual NK1R antagonists-SERT inhibitors may be useful in treating depression disorders. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.02.010
• 作为产物：
  描述：

  2-(but-3-enyl)-2-phenylhex-5-enenitrile 在 Grubbs catalyst first generation 、 sodium tetrahydroborate 、 硼烷四氢呋喃络合物 、 sodium hydride 、 二异丁基氢化铝 、 pyridinium chlorochromate 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 、 mineral oil 为溶剂， 反应 17.5h， 生成 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylcycloheptanone
  参考文献：
  名称：

  Discovery of disubstituted piperidines and homopiperidines as potent dual NK 1 receptor antagonists–serotonin reuptake transporter inhibitors for the treatment of depression

  摘要：

  This report describes the synthesis, structure-activity relationships and activity of piperidine, homopiperidine, and azocane derivatives combining NK1 receptor (NK1R) antagonism and serotonin reuptake transporter (SERT) inhibition. Our studies culminated in the discovery of piperidine 2 and homopiperidine 8 as potent dual NK1R antagonists-SERT inhibitors. Compound 2 demonstrated significant activity in the gerbil forced swimming test, suggesting that dual NK1R antagonists-SERT inhibitors may be useful in treating depression disorders. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.02.010

文献信息

• Cycloalkylamine derivatives as NK-1/SSRI antagonists
  申请人：Wu Yong-Jin

  公开号：US20060019992A1

  公开（公告）日：2006-01-26

  The present disclosure relates to chemical compounds and their use in human therapy. A specific embodiment relates to compounds of Formula (I) or an isomer, a pharmaceutically acceptable salt or solvate thereof and pharmaceutically acceptable formulations comprising said compounds useful for the treatment or prevention of conditions mediated by tachykinins and/or selective inhibition of serotonin reuptake transporter protein. The compounds act as dual NK-1 antagonists and selective serotonin reuptake inhibitors.

  本公开涉及化合物及其在人类治疗中的使用。具体实施方式涉及公式（I）的化合物或其异构体，药学上可接受的盐或溶剂，以及包含所述化合物的药学上可接受的制剂，用于治疗或预防由速激肽调节和/或选择性抑制血清素再摄取转运蛋白介导的疾病。这些化合物作为双重NK-1拮抗剂和选择性血清素再摄取抑制剂。
• US7494986B2
  申请人：——

  公开号：US7494986B2

  公开（公告）日：2009-02-24
• [EN] CYCLOALKYLAMINE DERIVATIVES AS NK-1 /SSRI ANTAGONISTS<br/>[FR] DERIVES DE CYCLOALKYLAMINE UTILISES COMME ANTAGONISTES NK-1 /SSRI
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2006023187A2

  公开（公告）日：2006-03-02

  The present disclosure relates to chemical compounds and their use in human therapy. A specific embodiment relates to compounds of Formula (I) or an isomer, a pharmaceutically acceptable salt or solvate thereof and pharmaceutically acceptable formulations comprising said compounds Formula (I); useful for the treatment or prevention of conditions mediated by tachykinins and/or selective inhibition of serotonin reuptake transporter protein. The compounds act as dual NK-1 antagonists and selective serotonin reuptake inhibitors.